In part because of the 2000 investment bubble, in part because Wall Street has rewarded their growth prospects with comparatively high valuations, Small Pharmas and proto-pharmas increasingly have among themselves the financial power and technological diversity to furnish each other much of the resources Big Pharma used to provide almost oligopolistically. Just as important: they've got far more willingness and incentive to do so.
The math is pretty simple: all the drivers being allocated proportionally, it's a lot easier to grow a small revenue base faster than a large one. And since investors reward growth more richly than cash flow, the biotechs' ability to grow should trump Big Pharma's stability.
But because the resources haven't been remotely equivalent, the biotech industry has always positioned itself, somewhat uncomfortably, to serve the...
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
Jana Grieb, European regulatory and market access legal expert at McDermott Will & Emery, explains why the healthtech and pharma industries are warming to the new EU health commissioner as he faces calls to make the MDR more “user friendly.”
While big pharma pours billions into creating new anti-aging molecules, a Belgian startup has taken a different path: combining existing safe drugs with AI precision. The early results suggest it might be onto something revolutionary.
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
